Mochida Pharmaceutical Co Stock

Mochida Pharmaceutical Co Liabilities 2024

Mochida Pharmaceutical Co Liabilities

30.83 B JPY

Ticker

4534.T

ISIN

JP3922800002

WKN

859288

In 2024, Mochida Pharmaceutical Co's total liabilities amounted to 30.83 B JPY, a -10.61% difference from the 34.49 B JPY total liabilities in the previous year.

Mochida Pharmaceutical Co Aktienanalyse

What does Mochida Pharmaceutical Co do?

Mochida Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company has been in the industry for over 100 years and has become one of the leading providers of medications and health products in Japan and worldwide. The history of Mochida Pharmaceutical begins in 1913 when Shoyo Mochida founded the company. Initially, the company specialized in the production of vitamins and later expanded its product range to include other pharmaceutical products. Over the following decades, the company steadily grew and expanded internationally. Today, Mochida Pharmaceutical is involved in various areas of healthcare. The company offers a wide range of medications for the treatment of various diseases and ailments, including cardiovascular diseases, diabetes, cancer, infectious diseases, and mental illnesses. Mochida Pharmaceutical is also involved in other areas of healthcare. The company manufactures and distributes various medical devices and diagnostics, including a wide range of medical instruments such as endoscopes and ultrasound devices, as well as tests and reagents for the diagnosis of infectious diseases and other conditions. A major focus of Mochida Pharmaceutical's business model is research and development of new products. The company has an extensive research and development department that continuously works on the development of new medications and technologies. Mochida Pharmaceutical collaborates closely with various universities and research institutes to develop new insights and technologies. In addition to the production and distribution of medications and medical devices, Mochida Pharmaceutical is also engaged in health promotion and prevention. The company offers various health services and products aimed at helping people live healthier lives and take better care of their health. Over the years, the company has achieved several important milestones. In 1970, Mochida Pharmaceutical successfully developed an immunosuppressive medication that is now known as Tacrolimus and is used to prevent organ transplant rejection. Other significant milestones include the introduction of medications for the treatment of diabetes and cancer, as well as the development of new technologies such as transdermal patches for medication administration. Mochida Pharmaceutical is now a globally operating company with branches in various countries. The company employs thousands of employees worldwide and has a strong presence in all major markets. The company is committed to further expanding its position as a leading provider of medical products and services and focusing on the needs of its customers and patients. Mochida Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Mochida Pharmaceutical Co's Liabilities

Mochida Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Mochida Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Mochida Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Mochida Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Mochida Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Mochida Pharmaceutical Co stock

What is the level of liabilities of Mochida Pharmaceutical Co this year?

Mochida Pharmaceutical Co has a debt balance of 30.83 B JPY this year.

What were the liabilities of Mochida Pharmaceutical Co compared to the previous year?

The liabilities of Mochida Pharmaceutical Co have increased by -10.61% dropped compared to the previous year.

What are the consequences of high debt for investors of Mochida Pharmaceutical Co?

High liabilities can pose a risk for investors of Mochida Pharmaceutical Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Mochida Pharmaceutical Co?

Low liabilities mean that Mochida Pharmaceutical Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Mochida Pharmaceutical Co affect the company?

An increase in liabilities of Mochida Pharmaceutical Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Mochida Pharmaceutical Co affect the company?

A decrease in the liabilities of Mochida Pharmaceutical Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Mochida Pharmaceutical Co?

Some factors that can influence the liabilities of Mochida Pharmaceutical Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Mochida Pharmaceutical Co so important for investors?

The liabilities of Mochida Pharmaceutical Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Mochida Pharmaceutical Co take to modify the liabilities?

To change its liabilities, Mochida Pharmaceutical Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Mochida Pharmaceutical Co pay?

Over the past 12 months, Mochida Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 2.25 %. For the coming 12 months, Mochida Pharmaceutical Co is expected to pay a dividend of 83.96 JPY.

What is the dividend yield of Mochida Pharmaceutical Co?

The current dividend yield of Mochida Pharmaceutical Co is 2.25 %.

When does Mochida Pharmaceutical Co pay dividends?

Mochida Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Mochida Pharmaceutical Co?

Mochida Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Mochida Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 83.96 JPY are expected. This corresponds to a dividend yield of 2.36 %.

In which sector is Mochida Pharmaceutical Co located?

Mochida Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mochida Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mochida Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Mochida Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Mochida Pharmaceutical Co in the year 2023?

In the year 2023, Mochida Pharmaceutical Co distributed 80 JPY as dividends.

In which currency does Mochida Pharmaceutical Co pay out the dividend?

The dividends of Mochida Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mochida Pharmaceutical Co

Our stock analysis for Mochida Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mochida Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.